Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742480 | 0.88 | MTNR1B (0.36) | MTNR1AMTNR1B | |
| SCHEMBL29357529 | 0.85 | NQO2 (0.38) | — | |
| SCHEMBL19742565 | 0.82 | MTNR1A (0.31) | MTNR1AMTNR1B | |
| SCHEMBL19742723 | 0.79 | MTNR1A (0.35) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL29355467 | 0.76 | ACACB (0.38) | MTNR1B | |
| SCHEMBL19742662 | 0.74 | MTNR1A (0.38) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL19742536 | 0.72 | EPHX2 (0.40) | L3MBTL1 | |
| SCHEMBL19742797 | 0.70 | MTNR1B (0.35) | MTNR1AMTNR1B | |
| SCHEMBL19742636 | 0.69 | CYP19A1 (0.34) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL29357552 | 0.69 | NQO2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | MTNR1A 850/4885MTNR1B 891/4885L3MBTL1 3627/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | MTNR1A 850/4885MTNR1B 891/4885L3MBTL1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.